Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRAP-ES vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased systemic vascular resistance and reduced blood pressure. The exact molecular mechanism involves inhibition of inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum and activation of guanylate cyclase, increasing c GMP levels.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension (alone or in combination with other antihypertensives),Off-label: Heart failure (as adjunctive therapy in African American patients)
Hypertension
Oral: 25-50 mg twice daily, max 200 mg/day. IV: 10-20 mg every 4-6 hours as needed.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours in severe cases).
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Primarily hepatic via N-acetylation by N-acetyltransferase 2 (NAT2). Metabolites include hydralazine pyruvic acid hydrazone, acetylhydralazine, and others.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Primarily renal (80-90% as unchanged drug); minor biliary/fecal (<10%).
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Approximately 87% bound to plasma proteins (primarily albumin).
Approximately 70-80% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: 50-60% due to first-pass metabolism; Intravenous: 100%.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
GFR 10-50 m L/min: Administer every 6-8 hours. GFR <10 m L/min: Administer every 8-12 hours.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use with caution, reduce dose by 75%.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Oral/IV: 0.1-0.5 mg/kg/dose every 6 hours; max initial dose 25 mg/dose.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Start at 10-25 mg twice daily; titrate slowly due to increased risk of hypotension and electrolyte disturbances.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
No FDA boxed warning for Hydralazine.
None.
May cause drug-induced lupus erythematosus (especially in slow acetylators),May cause peripheral neuritis (pyridoxine deficiency),May cause tachycardia, angina, or myocardial infarction in patients with coronary artery disease,May cause hypotension and renal impairment,Monitor for signs of lupus and neuropathy
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to hydralazine,Mitral valve rheumatic heart disease,Coronary artery disease (due to reflex tachycardia)
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Take with food to reduce gastrointestinal upset. Avoid high-tyramine foods if taking concomitant MAOIs, though hydralazine itself has no direct tyramine interaction. No specific food restrictions, but limit alcohol as it may exacerbate hypotension.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: No evidence of teratogenicity in human studies; animal studies show no fetal harm. Second and third trimesters: Associated with reduced placental perfusion and fetal growth restriction; risk of neonatal hypotension, hypoglycemia, and bradycardia if used near term.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Considered compatible with breastfeeding; monitor infant for hypotension and drowsiness.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Hypertension in pregnancy may require increased dosing due to increased volume of distribution and renal clearance; start with low doses and titrate based on blood pressure response; avoid severe hypotension to maintain placental perfusion.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Hydralazine, the active component, is a direct-acting vasodilator used for hypertension. It can cause a lupus-like syndrome, especially in slow acetylators. Monitor for tachycardia and fluid retention; consider concomitant beta-blocker and diuretic. Do not use as monotherapy for long-term management. Onset of action is rapid (15-20 min) IV, but oral bioavailability is variable (30-50%). Dose adjustments needed in renal impairment.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Report any joint pain, rash, fever, or unexplained bruising/bleeding.,May cause headaches or palpitations, especially early in therapy.,Avoid sudden discontinuation to prevent rebound hypertension.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRAP-ES vs ALDOCLOR-150, answered by our medical review team.
HYDRAP-ES is a Antihypertensive Combination that works by Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased systemic vascular resistance and reduced blood pressure. The exact molecular mechanism involves inhibition of inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum and activation of guanylate cyclase, increasing c GMP levels.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRAP-ES and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRAP-ES is: Oral: 25-50 mg twice daily, max 200 mg/day. IV: 10-20 mg every 4-6 hours as needed.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRAP-ES and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRAP-ES is classified as Category C. First trimester: No evidence of teratogenicity in human studies; animal studies show no fetal harm. Second and third trimesters: Associated with reduced placental perfusion and fet. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.